Literature DB >> 32913575

Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution's experience.

Onur Şahin1, Birkan Tatar1, Ceren Ekmekcioğlu1, Toghrul Aliyev1, Onur Odabaşı2.   

Abstract

BACKGROUND: Dentoalveolar surgery is a predisposing factor for medication related osteonecrosis of the jaw (MRONJ). The aim of our study was to evaluate the described surgical procedures to prevent the development of MRONJ after dentoalveolar surgery in patients receiving bisphosphonates.
MATERIAL AND METHODS: In this retrospective study, sixty-three dentoalveolar surgeries were performed on 44 patients taking bisphosphonate in accordance with the treatment procedures we described. The following procedures were applied to patients 1) use of antibiotics 2) performed dentoalveolar surgical procedures 3) fill the socket with leukocyte- and platelet-rich fibrin (L-PRF) 4) post-operative application of low level laser therapy through Nd: YAG laser 5) sutures were removed on post-op 14th day 6) long-term results were evaluated.
RESULTS: Healing of all patients was uneventful. Complete mucosal healing was achieved in all patients at 1 month. There is no failure was observed in long-term follow-up.
CONCLUSIONS: Because of the pathophysiology of MRONJ is not fully understood and has many risk factors, definitive protocols on prevention and treatment have not been established yet. Personal risk assessment is required for the prevention and treatment of MRONJ. The described surgical protocol may be considered to reduce the risk of developing MRONJ after dentoalveolar surgery due to its high success rate. Key words:Tooth extraction, medication related osteonecrosis of the jaw, preventive dentistry, L-PRF, low level laser therapy. Copyright:
© 2020 Medicina Oral S.L.

Entities:  

Year:  2020        PMID: 32913575      PMCID: PMC7474936          DOI: 10.4317/jced.56837

Source DB:  PubMed          Journal:  J Clin Exp Dent        ISSN: 1989-5488


  30 in total

Review 1.  Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases.

Authors:  O Filleul; E Crompot; S Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

2.  Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.

Authors:  Sven Otto; Christoph Pautke; Christine Opelz; Ines Westphal; Inga Drosse; Joanna Schwager; Frieder Bauss; Michael Ehrenfeld; Matthias Schieker
Journal:  J Oral Maxillofac Surg       Date:  2010-11       Impact factor: 1.895

3.  Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol.

Authors:  Matteo Scoletta; Valentina Arata; Paolo G Arduino; Ennio Lerda; Andrea Chiecchio; Giorgia Gallesio; Crispian Scully; Marco Mozzati
Journal:  J Oral Maxillofac Surg       Date:  2013-02-21       Impact factor: 1.895

Review 4.  Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Oliver Ristow; Sven Otto; Matthias Troeltzsch; Bettina Hohlweg-Majert; Christoph Pautke
Journal:  J Craniomaxillofac Surg       Date:  2014-11-22       Impact factor: 2.078

5.  Tooth extraction in patients on zoledronic acid therapy.

Authors:  Marco Mozzati; Valentina Arata; Giorgia Gallesio
Journal:  Oral Oncol       Date:  2012-04-05       Impact factor: 5.337

6.  Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?

Authors:  Sven Otto; Matthias Tröltzsch; Vesna Jambrovic; Sappasith Panya; Florian Probst; Oliver Ristow; Michael Ehrenfeld; Christoph Pautke
Journal:  J Craniomaxillofac Surg       Date:  2015-04-10       Impact factor: 2.078

7.  Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study.

Authors:  T Yamazaki; M Yamori; T Ishizaki; K Asai; K Goto; K Takahashi; T Nakayama; K Bessho
Journal:  Int J Oral Maxillofac Surg       Date:  2012-07-26       Impact factor: 2.789

8.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

9.  Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Marcus J Heufelder; Joerg Hendricks; Torsten Remmerbach; Bernhard Frerich; Alexander Hemprich; Frank Wilde
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-11-20

10.  Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy.

Authors:  Paolo Vescovi; Marco Meleti; Elisabetta Merigo; Maddalena Manfredi; Carlo Fornaini; Rebecca Guidotti; Samir Nammour
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-07-01
View more
  4 in total

Review 1.  The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes.

Authors:  Amerigo Giudice; Alessandro Antonelli; Emanuela Chiarella; Francesco Baudi; Tullio Barni; Anna Di Vito
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-25

Review 2.  Application of Fibrin Associated with Photobiomodulation as a Promising Strategy to Improve Regeneration in Tissue Engineering: A Systematic Review.

Authors:  Carlos Henrique Bertoni Reis; Daniela Vieira Buchaim; Adriana de Cássia Ortiz; Simone Ortiz Moura Fideles; Jefferson Aparecido Dias; Maria Angelica Miglino; Daniel de Bortoli Teixeira; Eliana de Souza Bastos Mazuqueli Pereira; Marcelo Rodrigues da Cunha; Rogerio Leone Buchaim
Journal:  Polymers (Basel)       Date:  2022-08-02       Impact factor: 4.967

3.  Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction.

Authors:  Catalina Moreno-Rabié; Laurence Lapauw; Hugo Gaêta-Araujo; André Ferreira-Leite; Wim Coucke; Tim van den Wyngaert; Reinhilde Jacobs
Journal:  Sci Rep       Date:  2022-07-04       Impact factor: 4.996

4.  The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ).

Authors:  Michele Miranda; Francesco Gianfreda; Carlo Raffone; Donato Antonacci; Valeria Pistilli; Patrizio Bollero
Journal:  Biomed Res Int       Date:  2021-05-13       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.